Acino appoints Jostein Davidsen as CEO | Nordic Capital

Acino appoints Jostein Davidsen as CEO

FEBRUARY 21 2014

Acino is pleased to announce, that Jostein Davidsen will join the Acino Group as its new Chief Executive Officer (CEO) by May 15, 2014, at the latest.

Since 2012, Jostein Davidsen serves as Head of Emerging Markets and appointed Corporate Officer at Takeda Pharmaceuticals International GmbH, based in Zurich (Switzerland). In this function, he is responsible for the EUR 1.5 billion business in the emerging growth economies of the Japanese pharmaceutical company Takeda. Prior to this, Jostein Davidsen had joined Nycomed Pharma in 1987 and held several senior management positions with the task of establishing and growing the company's business in Eastern Europe and the CIS-region. From 1994 to 2011 he built up the business in Russia-CIS to over EUR 500 million. In recognition of his outstanding achievements, Jostein Davidsen was nominated to the Top 100 Pharma Leader Award 2013/2014 as runner-up in the category Emerging Markets by Scrip Intelligence, the leading source of news and strategic analysis for the global pharmaceutical industry.

Håkan Björklund, Chairman of Acino Holding AG, commented: "We are delighted that Jostein Davidsen will join our company as its new CEO. His extensive experience as a leader in the pharmaceutical industry and his impressive track record in the emerging markets will be most valuable for the future development of our company."

About Acino
Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group is headquartered in Aesch BL.
On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, successfully completed its public tender offer for Acino Holding AG. Pharma Strategy Partners GmbH intends to effect a full takeover of Acino, and will delist the Acino shares from the stock exchange.

Robert Schmid
Media & Investor Relations
Phone +41 61 338 61 15